Chronic inflammatory demyelinating polyneuropathy in a diabetic patient: deterioration after intravenous immunoglobulins treatment and favorable response to steroid treatment.
The authors report the case of a 54-year old type-2 diabetic female patient with a Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). She progressively developed distal hypoesthesia and tetraparesis. She deteriorated after two courses of intravenous immunoglobulins (IVIG) administration and became rapidly wheelchair bound. After one month of steroid treatment, the patient was walking alone. This case raises the question whether IVIG is to be considered as first line treatment for diabetes associated CIDP.
Pedersen
K
K
Department of Neurology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium. kpederse@ulb.ac.be
Pandolfo
M
M
Mavroudakis
N
N
D001379:Azathioprine / Q000627:therapeutic use; D003929:Diabetic Neuropathies / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology*; D018450:Disease Progression; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects*; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D018908:Muscle Weakness / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D010525:Peripheral Nerves / Q000187:drug effects / Q000276:immunology / Q000503:physiopathology; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology*; D011782:Quadriplegia / Q000276:immunology / Q000503:physiopathology; D013256:Steroids / Q000627:therapeutic use*; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous; D013256:Steroids; D001379:Azathioprine; D008775:Methylprednisolone